GOODWILL

OMNIQ ANNOUNCES 2023 REVENUE OF $81.4 MILLION

Retrieved on: 
Monday, April 1, 2024
Growth, Tax, AI, Fintech, Impairment, Interest, Safety, Artificial intelligence, Cryptocurrency

OMNIQ reported revenue of $16 million for the quarter ended December 31, 2023.

Key Points: 
  • OMNIQ reported revenue of $16 million for the quarter ended December 31, 2023.
  • Cash balance on December 31, 2023, was approximately $1.7 million compared with $1.1 million on December 31, 2022.
  • OMNIQ reported revenue of $81.1 million for the year ended December 31, 2023, a decrease of $19.6 million from $100.8 million for the year ended December 31, 2022.
  • Our Gross Profit decreased to $15.7 million in the year that ended December 31, 2023, compared to $22.1 million in 2022.

Nanox Announces Fourth Quarter of 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, April 1, 2024
Research, PIN, LTD, Intermountain Health, Radiology, Exercise, Medical imaging, Patient, Health, Fatty liver disease, Action Replay, Policy, Sale, AI, D&O, Google Images, Teleradiology, NANO, GAAP, ARC, Depreciation, Marketing, FDA, Vertebral compression fracture, Hand, Cryptocurrency

PETAH TIKVA, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced results for the fourth quarter ended December 31, 2023 and provided a business update.

Key Points: 
  • Fourth Quarter 2023 Highlights and Recent Developments:
    Generated $2.4 million in revenue in the fourth quarter of 2023, compared to $2.1 million in the fourth quarter of 2022.
  • “I am incredibly proud to announce another strong quarter and year for Nanox,” said Erez Meltzer, Nanox Chief Executive Officer.
  • “First and foremost, we achieved a pivotal milestone in fiscal year 2023, getting FDA clearance for the Nanox ARC systems and deploying them in the key US market.
  • During the fourth quarter of 2023, Nanox AI continued to complete pilot programs with marketplaces, marketplace costumers and health organizations in anticipation of full deployment of its products.

Class 4-5 RIZON Electric Trucks Officially Hit the Streets Throughout California

Retrieved on: 
Wednesday, March 27, 2024
Diamond, Certification, Clothing, Transport, HVIP, Daimler, AC, Goodwill Industries, CARB, Velocity, Rail transport

RIZON trucks, exclusively distributed in the U.S. by Velocity EV, are set to revolutionize urban delivery applications by driving both economic and environmental sustainability.

Key Points: 
  • RIZON trucks, exclusively distributed in the U.S. by Velocity EV, are set to revolutionize urban delivery applications by driving both economic and environmental sustainability.
  • RIZON trucks can be customized with several different load body options for local goods movement, urban deliveries, and refrigerated deliveries.
  • Equipped with an electric power take-off (ePTO) controllable from the cab, these trucks offer added versatility for specialized equipment such as reefer belt drives and hydraulic pumps.
  • Velocity Truck Rental & Leasing: To provide California businesses with accessible zero-emission commercial vehicle solutions, Velocity has five e18L RIZON box trucks available for immediate rental or lease.

Accelecom Empowers Goodwill Industries of Kentucky's New Headquarters and Opportunity Center with Next-Generation Connectivity

Retrieved on: 
Tuesday, April 9, 2024
Disability, Opportunity Center, Employment, Marketing, Goodwill Industries

LOUISVILLE, Ky., April 9, 2024 /PRNewswire/ -- Accelecom , a leading provider of next-generation fiber solutions, today announced it will provide Goodwill Industries of Kentucky mission-critical connectivity to the nonprofit's new corporate headquarters and Opportunity Center in West Louisville.

Key Points: 
  • LOUISVILLE, Ky., April 9, 2024 /PRNewswire/ -- Accelecom , a leading provider of next-generation fiber solutions, today announced it will provide Goodwill Industries of Kentucky mission-critical connectivity to the nonprofit's new corporate headquarters and Opportunity Center in West Louisville.
  • Accelecom will be deploying a secure, reliable, and scalable network that can support the headquarters' growing digital needs.
  • Brad Kilbey, CEO of Accelecom said, "Accelecom is proud to partner with Goodwill Industries of Kentucky in their mission to provide job training and placement services to those in need.
  • In addition to providing Goodwill with the high-speed solutions it needs to operate, Accelecom will provide support ensuring maximum connectivity.

Abacus Life Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Thursday, March 21, 2024
Growth, Webcast, Intangibles, Policy, ROE, ABL, Asset, GAAP, Income tax, Eastern Time Zone, Total, Video game

ORLANDO, Fla., March 21, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a leading buyer of life insurance policies and vertically integrated alternative asset manager specializing in specialty insurance products, today reported results for the quarter and full year ended December 31, 2023.

Key Points: 
  • Total revenue for the fourth quarter of 2023 grew 25% to $23.6 million, compared to $18.8 million in the prior-year period.
  • Adjusted net income for the fourth quarter of 2023 was $5.9 million, compared to $11.0 million in the prior-year period.
  • Adjusted EBITDA for the fourth quarter of 2023 was $11.0 million, compared to $11.1 million in the prior-year period.
  • Total operating expenses for the fourth quarter of 2023 were $20.0 million, compared to $4.4 million in the prior-year period.

Cibus Reports Fourth Quarter Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 21, 2024
Research, Farmer, Gene editing, Entrepreneurship, HT1, Seed, HT2, Net, Bayer, PSR, Breeding, CBUS, WOSR, European Parliament, Agriculture

We've made significant progress on the commercial front with several advancements of these developed traits, including transfers to customers.

Key Points: 
  • We've made significant progress on the commercial front with several advancements of these developed traits, including transfers to customers.
  • This vote was a significant milestone for our entire industry and is a crucial step that will help Cibus usher in the gene editing era."
  • 2 Cibus Powered™ is the internal Cibus trait standard that ensures each Cibus trait meets minimum efficacy and quality assurance commercial requirements.
  • Cibus will host a live webcast, Thursday, March 21, 2024, at 4:30 p.m. Eastern Standard Time to discuss its fourth quarter 2023 financial results and provide a business update.

Alarum Announces Record of $1.7 Million Net Profit and $2.2 Million Adjusted EBITDA in the Fourth Quarter of 2023

Retrieved on: 
Thursday, March 14, 2024
Research, Growth, Three Months, Intelligence, Internet access, Internet, Acquisition, AI, Adjustment, Churn, Data collection, IP, Depreciation, Patent, NRR, Marketing, TEL, Video game

TEL AVIV, Israel, March 14, 2024 (GLOBE NEWSWIRE) -- Alarum Technologies Ltd. (Nasdaq, TASE: ALAR) (“Alarum” or the “Company”), a global provider of internet access and data collection solutions, today announced record financial results for the three months and full year periods, ended December 31, 2023. 

Key Points: 
  • IFRS net profit from continuing operations reached $1.7 million in the fourth quarter of 2023, compared to an IFRS net loss from continuing operations of $3.0 million in the fourth quarter of 2022.
  • Adjusted EBITDA for the fourth quarter of 2023 continued to grow, reaching $2.2 million, compared to Adjusted EBITDA loss of $2.0 million in the fourth quarter of 2022.
  • "I am proud to share the most successful quarter in the Company's history, as revenue, net profit and Adjusted EBITDA, all meaningfully exceeded results from the previous quarter.
  • Adjusted EBITDA was $5.2 million (2022: Adjusted EBITDA loss of $8.5 million).

NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results

Retrieved on: 
Tuesday, March 26, 2024
Biotechnology, Pharmaceutical, Optical, Health, Research and development, PIN, Growth, NBY, G&A, Co-promotion, Amazon (company), OTC, Marketing, NovaBay Pharmaceuticals, Pharmaceutical industry

(NYSE American: NBY) reports financial results for the three and 12 months ended December 31, 2023 and provides a business update.

Key Points: 
  • (NYSE American: NBY) reports financial results for the three and 12 months ended December 31, 2023 and provides a business update.
  • Net product revenue for the fourth quarter of 2023 included $2.8 million from the eyecare and wound care segment, and $0.9 million from the skincare segment.
  • Gross margin on net product revenue for the fourth quarter of 2023 was 49%, compared with 48% for the fourth quarter of 2022.
  • Research & development (R&D) expenses also decreased for the fourth quarter of 2023 to $4 thousand, versus $66 thousand for the prior-year period.

Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Tuesday, March 19, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, ChromeOS, Administration, MCL, ASH, Protocol, Patient, Tumor microenvironment, Holocene, G&A, CD70, Cancer, Tropism, Renal cell carcinoma, NHL, IND, Drug, Mantle cell lymphoma, Research and development, Society, TGF, ATM, Safety, FDA, Lupus nephritis, Autoimmunity, Pharmaceutical industry

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2023.
  • In December 2023, the FDA cleared the Company’s IND application for ADI-001 in lupus nephritis.
  • Adicet plans to initiate a Phase 1 study to evaluate the safety and efficacy of ADI-001 in lupus nephritis during the second quarter of 2024.
  • Preliminary clinical data from the trial are expected in the fourth quarter of 2024 or first quarter of 2025, pending study site activation progression and patient enrollment.

AM Best Affirms Credit Ratings of Most of CVS Health Corporation’s Aetna Inc. Subsidiaries; Withdraws Credit Ratings of Members of Texas Health Aetna

Retrieved on: 
Wednesday, March 13, 2024
Health, Professional Services, Insurance, Managed Care, Health Insurance, ERM, ALL, CVS Health, AM Best, Oak Street Health, Cell, Risk, Life, FSR, CVS, News, Acquisition, Credit, Pressure, Growth, Environment, Federal Home Loan Banks, Medicare, Medicare Advantage, Oak Street, Health insurance

In addition, AM Best has affirmed the FSR of A (Excellent) and the Long-Term ICRs of “a” (Excellent) of Texas Health + Aetna Health Insurance Company, as well as Texas Health + Aetna Health Plan Inc.

Key Points: 
  • In addition, AM Best has affirmed the FSR of A (Excellent) and the Long-Term ICRs of “a” (Excellent) of Texas Health + Aetna Health Insurance Company, as well as Texas Health + Aetna Health Plan Inc.
  • Both companies are domiciled in Arlington, TX, and collectively are referred to as Texas Health Aetna.
  • At the same time, AM Best has withdrawn the ratings of Texas Health Aetna as the companies have requested to no longer participate in AM Best’s interactive rating process.
  • Aetna Life & Health Group has moderate reinsurance leverage and its reinsurance arrangements differentiates Aetna from its health insurance peers.